Kotagal Kant
Nephrology · Cincinnati, OHNPI 1235195942
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,182 of the $4,643 with a category attached, or 68.5%. AstraZeneca accounts for 94.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $4,458 and has fallen 96.4% since, to $160 in 2025.
Across 12 payments — averaging $386.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Amgen$140
- Outset Medical Inc$94
- Ardelyx, Inc.$25
- Vantive US Healthcare LLC$20
Across 80 payments — averaging $4122.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$192K
- Biogen$43K
- CSL Behring$36K
- Gilead$22K
- AbbVie$14K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$14K
- plus $9K from 3 others
What the payments were for
- Consulting fees$3,18269%
- Travel & lodging$1,06023%
- Food & beverage$4029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $4,364 |
| Amgen | 1 | $140 |
| Outset Medical Inc | 1 | $94 |
| Ardelyx, Inc. | 1 | $25 |
| Vantive US Healthcare LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$140
How this compares
$4,643 in reported general payments places this provider in the 80th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 12 | $15,845 |
| ProsolParenteral Amino Acid 20% No.1 | 36 | $5,462 |
| Calcium Acetate | 16 | $1,063 |
| Nifedipine ErNifedipine | 11 | $284 |
| Lisinopril | 12 | $147 |
| Losartan Potassium | 18 | $142 |
| Furosemide | 16 | $92 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cincinnati
- Amit GovilCincinnati$298K
- Prabir Roy ChaudhuryCincinnati$205K
- Charuhas ThakarCincinnati$107K
- Chebel KhalilCincinnati$72K
- Arshdeep TindniCincinnati$41K
- Joseph KremerCincinnati$29K
- Tahir SajjadCincinnati$20K
- Silvi ShahCincinnati$14K
- Prakash GudsoorkarCincinnati$10K
- Ahmad AnjakCincinnati$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.